Submit Manuscript  

Article Details


A Short Scale Trial to Study and Evaluate the Safety and Efficacy of a Herbal Composition; Verona Anti-BPH Capsule to Treat Benign Prostatic Hyperplasia in Men Older than 40 Years of Age

Author(s):

Ifrah Hasan*, Saba Fatima Naqvi, Amraa Khan, Yamna Hasan and Mir UzairUllah   Pages 1 - 7 ( 7 )

Abstract:


Aims and objective: Benign prostatic hyperplasia (BPH), is a condition that causes proliferation of the cells of the prostate causing urine retention, renal insufficiency, bladder calculi, recurrent lower urinary tract infections (LUTS) and in complicated cases hematuria with unbearable pain. The trial was conducted to study the safety and efficacy of a novel herbal product Verona anti- BPH capsules at a local clinic of Sharafi Goth, Karachi Pakistan.

Introduction: Benign prostatic hyperplasia (BPH) is one of a major condition. The prevalence of the diseases increases to around 8-60% in men at age of 40 years which is caused mainly by a hormonal change, lifestyle changes or diet. The disease is mainly defined as an increased cellular proliferation of the prostate glands or an enlarged prostate. 50% men of age 65 years and above of the total population of Pakistan are at risk of having benign prostatic hyperplasia (BPH).

Method: This was a single blind, placebo control phase I clinical trial. A total of 35 patients were enrolled in the study, out of which 2 patients got dropped out. 23 patients received Verona anti-BPH capsules and 10 patients received placebo. The sample paired t-test was applied to evaluate the significant level.

Results: Verona Anti-BPH capsules were found safe and effective in the treatment of Benign prostatic hyperplasia (anti-BPH)

Conclusion: Verona Anti-BPH capsules were known to be effective with no harmful side effects.

Keywords:

Benign prostate hyperplasiBenign prostate hyperplasia, herbal

Affiliation:

Herbion Naturals, Medical affairs and Pharmacovigilance,C-21 Block 4 Gulshan-e-Iqbal, Herbion Pharma, Medical affairs, Herbion Pharma, Medical affairs, Herbion Pharma, Medical affairs, Herbion Pharma, Research and Development Department



Read Full-Text article